Search results for "FLUTICASONE PROPIONATE"
showing 7 items of 37 documents
487 The Influence of Inhaled Corticotherapy on the Growth and Development in Asthmatic Children
2012
Background Inhaled corticotherapy is the main anti-inflammatory controller type therapy in asthmatic children. Impaired growth as a result of long-term corticotherapy remains a disputed issue of topical interest for both endocrinologists, pneumologists and pediatricians. Objective The study evaluates the influence of long term small dose inhaled corticotherapy on growth and somatic development in asthmatic children. Methods Observational analytical study on 2 samples of subjects. The study group: 100 asthmatic children with small dose inhaled corticotherapy (beclomethasone dipropionate Becotide 200–400 µg/day or fluticasone propionate Flixotide 100–300 µg/day), for 24 months therapy. The co…
Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.
2014
International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…
The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma
2017
Introduction and Aim: As recognition of asthma heterogeneity increases and targeted treatment options are introduced, the future role of biomarkers (BM) in patient (pt) selection, monitoring and risk prediction will be important. We report baseline demographic and clinical characteristics from ARIETTA, an ongoing, prospective, longitudinal study assessing the relationship between BM and disease-related health outcomes in the real world. Methods: Pts with severe asthma (GINA steps 4-5) receiving daily inhaled corticosteroids (CS; fluticasone propionate ≥500 μg or equivalent) and ≥1 second controller medication were enrolled. Study enrollment is now complete. BM, clinical characteristics and …
Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells
2013
Cigarette smoke extracts (CSE) induce oxidative stress, an important feature in chronic obstructive pulmonary disease (COPD), and oxidative stress contributes to the poor clinical efficacy of corticosteroids in COPD patients. Carbocysteine, an antioxidant and mucolytic agent, is effec- tive in reducing the severity and the rate of exacerbations in COPD patients. The effects of carbocysteine on CSE-induced oxidative stress in bronchial epithelial cells as well as the comparison of these antioxidant effects of carbocysteine with those of fluticasone propionate are unknown. The present study was aimed to assess the effects of carbocysteine (10−4 M) in cell survival and intracellular reactive o…
1539 Length of Hospital Stay in Children with Acute Viral Pneumonia Treated with Corticosteroids, A Retrospective Study
2012
Background Corticosteroids with or without ephedrine may have positive effects in viral pneumonia treatment accelerating the time to resolution of symtpoms but the evidence is not strong enough to make specific recommandations. Objectives Evaluating the hospital length stay of the children with viral pneumonia treated with corticosteroids, single or in combination with ephedrine. Material and Methods The retrospective study included pacients admitted in our clinic with viral pneumonia during 2011. From 167 cases, 78 cases were selected according to specific criteria: patients having received cortisone (hydrocortisone hemisuccinate and/or fluticasone propionate) associated or not with ephedr…
Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simula…
2020
Omar S Usmani,1 Nicola Scichilone,2 Benjamin Mignot,3 Dennis Belmans,3 Cedric Van Holsbeke,3 Jan De Backer,3 Roberta De Maria,4 Erika Cuoghi,4 Eva Topole,4 George Georges4 1Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK; 2PROMISE Department of Medicine, University of Palermo, Palermo, Italy; 3FLUIDDA, Kontich, Belgium; 4Chiesi Farmaceutici, SpA, Parma, ItalyCorrespondence: George GeorgesChiesi USA Inc., 175 Regency Woods Place, Ste. 600, Cary, NC 27518, USATel +1 (919) 678 6611 x1536Email george.georges@chiesi.comIntroduction: There is a clear correlation between small airways dysfunction and poor clinical outcomes in patients with chronic obstructiv…
A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis
1999
Fluticasone propionate aqueous nasal spray (FPANS) is a topically active glucocorticoid which has been successfully used for the treatment of seasonal allergic rhinitis (SAR). Topical levocabastine is a highly selective H1 antagonist which has been proposed as an alternative treatment of SAR. The purpose of this study was to compare the clinical efficacy of two topical nasal treatments, FPANS and levocabastine, in the treatment of SAR. Additionally, the effect of treatments on nasal inflammation was examined during natural pollen exposure. A group of 288 adolescent and adult patients with at least a 2-year history of SAR to seasonal pollens participated in a multicenter, doubleblind, double…